Boehringer Ingelheim, caesar and the Max-Planck-Society announce an

Independent Junior Research Group

"Cellular Degradation Mechanisms in Neurodegenerative Diseases"

The candidate should be interested in general mechanisms of cellular degradation pathways during neurodegenerative diseases in particular autophagocytosis or degradation in the endosome, lysosome or proteasome.
 
The Junior Research Group will be established at the center of advanced european studies and research in Bonn (caesar; www.caesar.de), an interdisciplinary research center associated with the Max-Planck-Society.
 
Funding of the Research Group covers a set-up package, the position of the group leader, a technician, one PhD and one post-doctoral fellowship, secretarial support, plus consumables, and is (initially) for 5 years. The successful candidate should have experience in one of the above mentioned research areas.
Applications should include a CV, a list of publications, a one-page summary of scientific achievements, a two-page research plan and two letters of recommendation. Successful candidates will be invited to a symposium in May 2010 in Bonn.
 
Boehringer Ingelheim is a family-owned, research-driven global pharmaceutical company, founded in 1885 and committed to the goal of serving humankind through research into diseases and the development of new drugs and therapies. Boehringer Ingelheim operates with 41,300 employees in 47 countries across the globe.

caesar (center of advanced european studies and research, located in Bonn, Germany) is conducting research in the field of neurosciences focussing on sensory systems, neurophotonics and neurodegenerative diseases. State-of-the-art techniques for imaging, molecular biology as well as chemical and material sciences open excellent opportunities in basic and applied research, caesar is associated with the Max-Planck-Society.

The Max Planck Society for the Advancement of Science is an independent, non-profit research organization that primarily promotes and supports basic research. The society currently operates 80 institutes and research facilities with more than 23,400 employees, including 4,400 scientists.
 
Boehringer Ingelheim, caesar and the Max-Planck-Society are committed to equal opportunities and to employing disabled persons.
 
For further information please contact Prof. Dr. U. B. Kaupp, phone: +49 (0)228 9656 100 or u.b.kaupp@caesar.de
 
Please send your application no later than April 15, 2010 to: